(A1)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/30435 A1

(51) International Patent Classification[7]: A61K 35/28, A61P 37/04

(21) International Application Number: PCT/AU01/01291

(22) International Filing Date: 15 October 2001 (15 10 2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PR 0745 13 October 2000 (13 10 2000) AU

(71) Applicant *(for all designated States except US)*: **MONASH UNIVERSITY** [AU/AU]; Wellington Road, Clayton, Victoria 3168 (AU).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **BOYD, Richard, Lennox** [AU/AU]; 60 Linacre Road, Hampton, Victoria 3188 (AU).

(74) Agent: **FB RICE & CO**, PO Box 668, Carlton South, Carlton, Victoria 3053 (AU)

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

162162

WO 02/30435 A1

(54) Title: TREATMENT OF T CELL DISORDERS

(57) Abstract: The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signalling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC)